首页 > 最新文献

中华妇产科杂志最新文献

英文 中文
[Safety and long-term efficacy of transvaginal reconstructive pelvic surgery for severe pelvic organ prolapse in elderly women aged 70 years and over]. [经阴道盆腔重建术治疗70岁及以上老年妇女严重盆腔器官脱垂的安全性和远期疗效]。
Pub Date : 2025-08-25 DOI: 10.3760/cma.j.cn112141-20250220-00058
X L Zhang, Y X Lu, W J Shen, Y Zhao, K Niu, W Y Wang, L Qin, J J Yan

Objective: To explore the safety and long-term efficacy of transvaginal reconstructive pelvic surgery (TVRPS) in ≥70-year-old women with severe pelvic organ prolapse (POP). Methods: A single-center, prospective cohort study was conducted on 343 elderly women patients with severe POP who received TVRPS at the Fourth Medical Center, Chinese PLA General Hospital, Medical School of Chinese PLA from March 2007 to September 2024. There were 297 cases (86.6%, 297/343) of Ⅲ degree and 46 cases (13.4%, 46/343) of Ⅳ degree prolapse respectively. Among them, anterior pelvic prolapse accounted for 80.8% (277/343), and those with prolapse in two or more sites accounted for 30.0% (103/343). The age was (74.2±3.4) years (range: 70 to 89 years old). There were 300 cases (87.5%, 300/343) with more than one internal medicine disease. Preoperative general conditions were assessed using American Society of Anesthesiologists physical status classification system (ASA) and American College of Surgeons National Surgical Quality Improvement Program-frailty index (ACS NSQIP-FI). TVRPS surgeries included transvaginal hysterectomy, salpingooophorectomy, high uterosacral ligament suspension, sacrospinous ligament fixation, native tissue and mesh repair of the anterior and posterior vaginal walls, mid-urethral sling for anti-urinary incontinence, and levator anal muscle folding suture and perineal repair. Perioperative complications were evaluated using Clavien-Dindo classification system. The objective effect of TVRPS was determined based on pelvic organ prolapse quantification system (POP-Q), and the subjective results were evaluated using pelvic floor distress inventory-short form 20 (PFDI-20), pelvic floor impact questionnaire-short form 7 (PFIQ-7) and patient global impression of improvement (PGI-I). Results: All patients had a preoperative ASA grade of ≤gradeⅡ, and ACS NSQIP-FI score of ≤0.27. All patients safely and successfully underwent all TVRPS surgeries. The operation time was (154.2±43.2) minutes. The perioperative morbidity and mortality rate were 0.6% (2/343) and 0 (0/343) respectively. None of the patient needed blood transfusion. The follow-up time was (7.5±4.3) years, with the longest being 17 years. Thirty-four cases (9.9%, 34/343) were lost to follow-up, and 22 cases (6.4%, 22/343) died of internal diseases during the follow-up period. The point values of Aa, Ba, C, Ap and Bp in the POP-Q system were significantly decreased after the operation (all P<0.01), the genital hiatus was significantly shortened (all P<0.01), and the perineal body was significantly elongated (all P<0.01). The scores of PFDI-20 and PFIQ-7 were significantly lower than those before the operation (all P<0.01). There were 332 cases (96.8%, 332/343) with an overall symptom impression improvement score of PGI-I≤2. Conclusion: The results on 343 elderly women with severe POP aged an average of 74.2 years show that for elderly

目的:探讨经阴道盆腔重建术(TVRPS)治疗≥70岁严重盆腔器官脱垂(POP)的安全性和远期疗效。方法:对2007年3月至2024年9月在解放军医学院总医院第四医学中心接受TVRPS治疗的343例老年女性重症POP患者进行单中心前瞻性队列研究。Ⅲ度脱垂297例(86.6%,297/343),Ⅳ度脱垂46例(13.4%,46/343)。其中盆腔前脱垂占80.8%(277/343),两处及以上脱垂占30.0%(103/343)。年龄(74.2±3.4)岁,年龄范围70 ~ 89岁。300例(87.5%,300/343)存在一种以上内科疾病。术前一般情况采用美国麻醉医师学会身体状态分类系统(ASA)和美国外科医师学会国家手术质量改进计划-虚弱指数(ACS NSQIP-FI)进行评估。TVRPS手术包括经阴道子宫切除术、输卵管卵巢切除术、子宫骶高位韧带悬吊、骶棘韧带固定、阴道前后壁天然组织及补片修复、尿道中悬吊防尿失禁、提肛肌折叠缝合及会阴修复。采用Clavien-Dindo分类系统对围手术期并发症进行评价。采用盆腔器官脱垂量化系统(POP-Q)评价TVRPS的客观效果,采用盆底痛苦短表20 (PFDI-20)、盆底影响问卷短表7 (PFIQ-7)和患者总体改善印象(PGI-I)评价主观效果。结果:所有患者术前ASA分级≤Ⅱ级,ACS NSQIP-FI评分≤0.27。所有患者均安全成功地完成了TVRPS手术。手术时间为(154.2±43.2)min。围手术期发病率和死亡率分别为0.6%(2/343)和0(0/343)。没有一个病人需要输血。随访时间为(7.5±4.3)年,最长为17年。失访34例(9.9%,34/343),随访期间因内科疾病死亡22例(6.4%,22/343)。术后POP-Q系统Aa、Ba、C、Ap、Bp点值均显著降低(均为ppppp)。343例平均年龄74.2岁的老年重度POP女性患者的结果表明,对于仍有保留阴道愿望且不符合阴道膨出条件的老年POP患者,只要术前对整体情况有全面的了解和严格的评估,TVRPS是一种安全、可行、持久的治疗方法。
{"title":"[Safety and long-term efficacy of transvaginal reconstructive pelvic surgery for severe pelvic organ prolapse in elderly women aged 70 years and over].","authors":"X L Zhang, Y X Lu, W J Shen, Y Zhao, K Niu, W Y Wang, L Qin, J J Yan","doi":"10.3760/cma.j.cn112141-20250220-00058","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250220-00058","url":null,"abstract":"<p><p><b>Objective:</b> To explore the safety and long-term efficacy of transvaginal reconstructive pelvic surgery (TVRPS) in ≥70-year-old women with severe pelvic organ prolapse (POP). <b>Methods:</b> A single-center, prospective cohort study was conducted on 343 elderly women patients with severe POP who received TVRPS at the Fourth Medical Center, Chinese PLA General Hospital, Medical School of Chinese PLA from March 2007 to September 2024. There were 297 cases (86.6%, 297/343) of Ⅲ degree and 46 cases (13.4%, 46/343) of Ⅳ degree prolapse respectively. Among them, anterior pelvic prolapse accounted for 80.8% (277/343), and those with prolapse in two or more sites accounted for 30.0% (103/343). The age was (74.2±3.4) years (range: 70 to 89 years old). There were 300 cases (87.5%, 300/343) with more than one internal medicine disease. Preoperative general conditions were assessed using American Society of Anesthesiologists physical status classification system (ASA) and American College of Surgeons National Surgical Quality Improvement Program-frailty index (ACS NSQIP-FI). TVRPS surgeries included transvaginal hysterectomy, salpingooophorectomy, high uterosacral ligament suspension, sacrospinous ligament fixation, native tissue and mesh repair of the anterior and posterior vaginal walls, mid-urethral sling for anti-urinary incontinence, and levator anal muscle folding suture and perineal repair. Perioperative complications were evaluated using Clavien-Dindo classification system. The objective effect of TVRPS was determined based on pelvic organ prolapse quantification system (POP-Q), and the subjective results were evaluated using pelvic floor distress inventory-short form 20 (PFDI-20), pelvic floor impact questionnaire-short form 7 (PFIQ-7) and patient global impression of improvement (PGI-I). <b>Results:</b> All patients had a preoperative ASA grade of ≤gradeⅡ, and ACS NSQIP-FI score of ≤0.27. All patients safely and successfully underwent all TVRPS surgeries. The operation time was (154.2±43.2) minutes. The perioperative morbidity and mortality rate were 0.6% (2/343) and 0 (0/343) respectively. None of the patient needed blood transfusion. The follow-up time was (7.5±4.3) years, with the longest being 17 years. Thirty-four cases (9.9%, 34/343) were lost to follow-up, and 22 cases (6.4%, 22/343) died of internal diseases during the follow-up period. The point values of Aa, Ba, C, Ap and Bp in the POP-Q system were significantly decreased after the operation (all <i>P</i><0.01), the genital hiatus was significantly shortened (all <i>P</i><0.01), and the perineal body was significantly elongated (all <i>P</i><0.01). The scores of PFDI-20 and PFIQ-7 were significantly lower than those before the operation (all <i>P</i><0.01). There were 332 cases (96.8%, 332/343) with an overall symptom impression improvement score of PGI-I≤2. <b>Conclusion:</b> The results on 343 elderly women with severe POP aged an average of 74.2 years show that for elderly ","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 8","pages":"627-636"},"PeriodicalIF":0.0,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Safety and efficacy of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer after first-line PARPi maintenance therapy]. [铂敏感复发卵巢癌患者在一线PARPi维持治疗后二次细胞减少手术的安全性和有效性]。
Pub Date : 2025-08-25 DOI: 10.3760/cma.j.cn112141-20241106-00591
Y X Zhao, H W Yao, J Zeng, Y C Sun, N Li, G W Yuan, N Li, L Y Wu
<p><p><b>Objective:</b> To investigate the effectiveness and safety of secondary cytoreductive surgery (SCS) in patients with platinum-sensitive recurrent epithelial ovarian cancer who progressed after first-line maintenance therapy with poly adenosine diphosphate ribose polymerase inhibitor (PARPi). <b>Methods:</b> Clinical pathological data and prognostic information were retrospectively collected from 30 ovarian cancer patients who underwent SCS between January 2018 and June 2024. The Kaplan-Meier method was used to analyze the second progression-free survival (PFS2) time and 3-year overall survival (OS) rate. <b>Results:</b> (1) Primary treatment: the median age at diagnosis was 51.3 years. A total of 40% (12/30) patients underwent primary debulking surgery with an expectation of achieving no gross residual disease (R0), while 60% (18/30) received neoadjuvant chemotherapy and interval debulking surgery. Optimal cytoreduction was achieved in 93% (28/30) of patients. BRCA1/2 gene testing was performed in 29 patients (testing rate 97%, 29/30), identifying 11 BRCA-mutated (37%, 11/30) and 18 BRCA wild-type (60%, 18/30) patients. The median duration of PARPi maintenance therapy among the 30 patients was 11.9 months; patients with BRCA gene mutations had a median duration of 19.2 months, while those with BRCA wild-type had a median duration of 10.1 months. (2) Secondary surgery: pathologically confirmed recurrence patterns, single lesion in 9 patients (30%, 9/30), oligo-lesion (2 lesions) in 3 patients (10%, 3/30), and multi-lesion (≥3 lesions) in 18 patients (60%, 18/30). Among the 30 patients, optimal cytoreduction was achieved in 97% (29/30) of SCS patients, with suboptimal cytoreduction in 1 patient (3%, 1/30). Adjuvant chemotherapy included platinum+paclitaxel in 24 (80%, 24/30) patients and platinum+liposomal doxorubicin in 6 (20%, 6/30) patients. PARPi re-treatment was administered to 17 patients (57%, 17/30) after chemotherapy. (3) Efficacy and safety: as of the follow-up cutoff in June 2024, the median follow-up time was 28.0 months. A total of 19 (63%, 19/30) patients experienced the next recurrence. The median PFS2 time after SCS was 18.5 months. Recurrence occurred in 7 BRCA-mutated and 12 BRCA gene wild-type patients. Median PFS2 time was significantly longer in BRCA-mutated patients compared to BRCA wild-type patients (25.7 vs 14.1 months; <i>P</i>=0.028). Three deaths occurred during follow-up, resulting in a 3-year OS rate of 90%. Among the 30 patients, postoperative complications occurred in 4 patients (13%, 4/30). One patient developed a ureteral fistula on 7 days post-SCS requiring ureteral stenting, and one patient was transferred to the intensive care unit on 1 day post-SCS due to hypovolemic shock. No deaths occurred within 30 days after SCS. <b>Conclusion:</b> For platinum-sensitive recurrent ovarian cancer patients progressed after first-line PARPi maintenance therapy who are anticipated to achieve R0 resection, SCS represen
目的:探讨二次细胞减少手术(SCS)治疗铂敏感复发性上皮性卵巢癌患者在接受多腺苷二磷酸核糖聚合酶抑制剂(PARPi)一线维持治疗后进展的有效性和安全性。方法:回顾性收集2018年1月至2024年6月30例接受SCS治疗的卵巢癌患者的临床病理资料和预后信息。Kaplan-Meier法分析第二次无进展生存期(PFS2)时间和3年总生存期(OS)率。结果:(1)初治:诊断时中位年龄51.3岁。共有40%(12/30)的患者接受了预期无总残留病变(R0)的原发性减容手术,60%(18/30)的患者接受了新辅助化疗和间隔减容手术。93%(28/30)的患者实现了最佳的细胞减少。29例患者进行BRCA1/2基因检测(检测率97%,29/30),鉴定出BRCA突变型11例(37%,11/30),BRCA野生型18例(60%,18/30)。30例患者PARPi维持治疗的中位持续时间为11.9个月;BRCA基因突变患者的中位病程为19.2个月,而BRCA野生型患者的中位病程为10.1个月。(2)二次手术:病理证实的复发类型,单灶9例(30%,9/30),少灶(2个)3例(10%,3/30),多灶(≥3个)18例(60%,18/30)。在30例患者中,97%(29/30)的SCS患者达到最佳细胞减少,1例患者达到次优细胞减少(3%,1/30)。辅助化疗包括铂+紫杉醇24例(80%,24/30),铂+阿霉素脂质体6例(20%,6/30)。化疗后再给PARPi治疗17例(57%,17/30)。(3)疗效和安全性:截至2024年6月随访截止,中位随访时间为28.0个月。共有19例(63%,19/30)患者再次复发。SCS后的中位PFS2时间为18.5个月。7例BRCA突变型患者和12例BRCA野生型患者出现复发。BRCA突变患者的中位PFS2时间明显长于BRCA野生型患者(25.7个月vs 14.1个月;P=0.028)。随访期间发生3例死亡,3年生存率为90%。30例患者中出现术后并发症4例(13%,4/30)。1例患者在scs后7天出现输尿管瘘,需要输尿管支架植入,1例患者因低血容量性休克在scs后1天转入重症监护病房。SCS后30天内未发生死亡。结论:对于铂敏感的复发性卵巢癌患者,在一线PARPi维持治疗后进展进展,并有望实现R0切除,SCS是一种安全有效的二线治疗选择。
{"title":"[Safety and efficacy of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer after first-line PARPi maintenance therapy].","authors":"Y X Zhao, H W Yao, J Zeng, Y C Sun, N Li, G W Yuan, N Li, L Y Wu","doi":"10.3760/cma.j.cn112141-20241106-00591","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20241106-00591","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the effectiveness and safety of secondary cytoreductive surgery (SCS) in patients with platinum-sensitive recurrent epithelial ovarian cancer who progressed after first-line maintenance therapy with poly adenosine diphosphate ribose polymerase inhibitor (PARPi). &lt;b&gt;Methods:&lt;/b&gt; Clinical pathological data and prognostic information were retrospectively collected from 30 ovarian cancer patients who underwent SCS between January 2018 and June 2024. The Kaplan-Meier method was used to analyze the second progression-free survival (PFS2) time and 3-year overall survival (OS) rate. &lt;b&gt;Results:&lt;/b&gt; (1) Primary treatment: the median age at diagnosis was 51.3 years. A total of 40% (12/30) patients underwent primary debulking surgery with an expectation of achieving no gross residual disease (R0), while 60% (18/30) received neoadjuvant chemotherapy and interval debulking surgery. Optimal cytoreduction was achieved in 93% (28/30) of patients. BRCA1/2 gene testing was performed in 29 patients (testing rate 97%, 29/30), identifying 11 BRCA-mutated (37%, 11/30) and 18 BRCA wild-type (60%, 18/30) patients. The median duration of PARPi maintenance therapy among the 30 patients was 11.9 months; patients with BRCA gene mutations had a median duration of 19.2 months, while those with BRCA wild-type had a median duration of 10.1 months. (2) Secondary surgery: pathologically confirmed recurrence patterns, single lesion in 9 patients (30%, 9/30), oligo-lesion (2 lesions) in 3 patients (10%, 3/30), and multi-lesion (≥3 lesions) in 18 patients (60%, 18/30). Among the 30 patients, optimal cytoreduction was achieved in 97% (29/30) of SCS patients, with suboptimal cytoreduction in 1 patient (3%, 1/30). Adjuvant chemotherapy included platinum+paclitaxel in 24 (80%, 24/30) patients and platinum+liposomal doxorubicin in 6 (20%, 6/30) patients. PARPi re-treatment was administered to 17 patients (57%, 17/30) after chemotherapy. (3) Efficacy and safety: as of the follow-up cutoff in June 2024, the median follow-up time was 28.0 months. A total of 19 (63%, 19/30) patients experienced the next recurrence. The median PFS2 time after SCS was 18.5 months. Recurrence occurred in 7 BRCA-mutated and 12 BRCA gene wild-type patients. Median PFS2 time was significantly longer in BRCA-mutated patients compared to BRCA wild-type patients (25.7 vs 14.1 months; &lt;i&gt;P&lt;/i&gt;=0.028). Three deaths occurred during follow-up, resulting in a 3-year OS rate of 90%. Among the 30 patients, postoperative complications occurred in 4 patients (13%, 4/30). One patient developed a ureteral fistula on 7 days post-SCS requiring ureteral stenting, and one patient was transferred to the intensive care unit on 1 day post-SCS due to hypovolemic shock. No deaths occurred within 30 days after SCS. &lt;b&gt;Conclusion:&lt;/b&gt; For platinum-sensitive recurrent ovarian cancer patients progressed after first-line PARPi maintenance therapy who are anticipated to achieve R0 resection, SCS represen","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 8","pages":"600-607"},"PeriodicalIF":0.0,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Impact of the number of cesarean deliveries on adverse pregnancy outcomes of cesarean section in a single-center cohort study]. [单中心队列研究中剖宫产次数对剖宫产不良妊娠结局的影响]。
Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn112141-20250121-00032
M Hu, L Lin, L L Du, Z P Yan, S J Luo, W Sun, S Lu, Y T He, F He, D J Chen

Objective: To investigate the impact of the number of cesarean deliveries on adverse maternal and neonatal outcomes. Methods: A retrospective analysis was conducted on 11 904 singleton pregnant women who underwent cesarean delivery at the Third Affiliated Hospital of Guangzhou Medical University from January 1st, 2019 to December 31st, 2023. The women were grouped according to the number of cesarean deliveries: those undergoing their first cesarean delivery (1CD group, 7 231 cases), those undergoing their second cesarean delivery (2CD group, 3 749 cases), those undergoing their third cesarean delivery (3CD group, 841 cases), and those undergoing their fourth or more cesarean deliveries (4CD group, 83 cases). Differences in clinical characteristics, related surgical procedures, and adverse maternal and neonatal outcomes among the groups were compared. Binary logistic regression analysis was used to assess the impact of the number of cesarean deliveries on related surgical procedures and adverse maternal and neonatal outcomes. Results: (1) During the 5-year period, the total number of women undergoing cesarean delivery in our hospital showed a slight downward trend, while the proportion of women undergoing three or more cesarean deliveries increased. (2) Compared with women undergoing their first cesarean delivery, women in each repeat cesarean delivery group were older, had higher proportions of advanced maternal age and pre-pregnancy body mass index, and had more pregnancies, deliveries, and induced abortions; the incidence of placenta previa, placental implantation, antepartum hemorrhage, gestational hyperglycemia, and failed trial of labor requiring conversion to surgery was higher, while the incidence of premature rupture of membranes was lower; the proportions of ureteral stent placement, adhesiolysis of the pelvic and abdominal cavities, uterine rupture, uterine reconstruction, uterine artery ligation, hysterectomy, postpartum hemorrhage, and postoperative intestinal obstruction were higher, and the amount of postpartum hemorrhage was greater; the gestational age at delivery of neonates was earlier, but the rates of preterm birth at 28-31+6 and 32-33+6 weeks of gestation were lower; the differences were statistically significant (P<0.05) for all comparisons. (3) The number of cesarean deliveries was not an independent risk factor for the dose-dependent occurrence of placenta previa (aOR=0.99, 95%CI: 0.98-1.01; P=0.261). In women without placenta previa, the number of cesarean deliveries was not a risk factor for placental implantation (aOR=1.12, 95%CI: 0.90-1.39; P=0.320). However, in women with placenta previa, the number of cesarean deliveries was a risk factor for placental implantation (aOR=4.01, 95%CI: 3.08-5.22; P<0.001). In the overall population, the number of cesarean deliveries was a risk factor for ureteral stent

目的:探讨剖宫产次数对产妇及新生儿不良结局的影响。方法:回顾性分析2019年1月1日至2023年12月31日在广州医科大学第三附属医院剖宫产的1904例单胎孕妇。根据剖宫产次数分组:第一次剖宫产(1CD组,7 231例)、第二次剖宫产(2CD组,3 749例)、第三次剖宫产(3CD组,841例)、第四次及以上剖宫产(4CD组,83例)。比较两组患者在临床特征、相关外科手术、孕产妇和新生儿不良结局方面的差异。采用二元logistic回归分析评估剖宫产次数对相关外科手术及孕产妇和新生儿不良结局的影响。结果:(1)5年期间,我院剖宫产总人数略有下降,三次及以上剖宫产比例有所上升。(2)与首次剖宫产妇女相比,各重复剖宫产组妇女年龄较大,高龄产妇比例和孕前体重指数较高,妊娠、分娩和人工流产次数较多;前置胎盘、胎盘植入、产前出血、妊娠高血糖、试产失败转手术发生率较高,而胎膜早破发生率较低;输尿管支架置入术、盆腔、腹腔粘连松解术、子宫破裂、子宫重建术、子宫动脉结扎术、子宫切除术、产后出血、术后肠梗阻的比例较高,产后出血量较大;分娩时胎龄较早,但28-31+6周和32-33+6周早产率较低;差异有统计学意义(POR=0.99, 95%CI: 0.98 ~ 1.01;P = 0.261)。在没有前置胎盘的妇女中,剖宫产次数不是胎盘植入的危险因素(aOR=1.12, 95%CI: 0.90-1.39;P = 0.320)。然而,在有前置胎盘的妇女中,剖宫产次数是胎盘植入的危险因素(aOR=4.01, 95%CI: 3.08-5.22;ppp结论:剖宫产次数可能导致不良的孕产妇和新生儿结局,但这种关系不是简单的剂量依赖关系。推测严重不良孕产妇及新生儿结局的发生与孕产妇并发症及合并症,以及是否接受多学科综合管理更为密切相关。
{"title":"[Impact of the number of cesarean deliveries on adverse pregnancy outcomes of cesarean section in a single-center cohort study].","authors":"M Hu, L Lin, L L Du, Z P Yan, S J Luo, W Sun, S Lu, Y T He, F He, D J Chen","doi":"10.3760/cma.j.cn112141-20250121-00032","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250121-00032","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the impact of the number of cesarean deliveries on adverse maternal and neonatal outcomes. <b>Methods:</b> A retrospective analysis was conducted on 11 904 singleton pregnant women who underwent cesarean delivery at the Third Affiliated Hospital of Guangzhou Medical University from January 1st, 2019 to December 31st, 2023. The women were grouped according to the number of cesarean deliveries: those undergoing their first cesarean delivery (1CD group, 7 231 cases), those undergoing their second cesarean delivery (2CD group, 3 749 cases), those undergoing their third cesarean delivery (3CD group, 841 cases), and those undergoing their fourth or more cesarean deliveries (4CD group, 83 cases). Differences in clinical characteristics, related surgical procedures, and adverse maternal and neonatal outcomes among the groups were compared. Binary logistic regression analysis was used to assess the impact of the number of cesarean deliveries on related surgical procedures and adverse maternal and neonatal outcomes. <b>Results:</b> (1) During the 5-year period, the total number of women undergoing cesarean delivery in our hospital showed a slight downward trend, while the proportion of women undergoing three or more cesarean deliveries increased. (2) Compared with women undergoing their first cesarean delivery, women in each repeat cesarean delivery group were older, had higher proportions of advanced maternal age and pre-pregnancy body mass index, and had more pregnancies, deliveries, and induced abortions; the incidence of placenta previa, placental implantation, antepartum hemorrhage, gestational hyperglycemia, and failed trial of labor requiring conversion to surgery was higher, while the incidence of premature rupture of membranes was lower; the proportions of ureteral stent placement, adhesiolysis of the pelvic and abdominal cavities, uterine rupture, uterine reconstruction, uterine artery ligation, hysterectomy, postpartum hemorrhage, and postoperative intestinal obstruction were higher, and the amount of postpartum hemorrhage was greater; the gestational age at delivery of neonates was earlier, but the rates of preterm birth at 28-31<sup>+6</sup> and 32-33<sup>+6</sup> weeks of gestation were lower; the differences were statistically significant (<i>P</i><0.05) for all comparisons. (3) The number of cesarean deliveries was not an independent risk factor for the dose-dependent occurrence of placenta previa (a<i>OR</i>=0.99, 95%<i>CI</i>: 0.98-1.01; <i>P</i>=0.261). In women without placenta previa, the number of cesarean deliveries was not a risk factor for placental implantation (a<i>OR</i>=1.12, 95%<i>CI</i>: 0.90-1.39; <i>P</i>=0.320). However, in women with placenta previa, the number of cesarean deliveries was a risk factor for placental implantation (a<i>OR</i>=4.01, 95%<i>CI</i>: 3.08-5.22; <i>P</i><0.001). In the overall population, the number of cesarean deliveries was a risk factor for ureteral stent ","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 6","pages":"430-438"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Endometriosis-associated ovarian mesonephric-like adenocarcinoma:a clinicopathological analysis of 9 cases]. 【子宫内膜异位症合并卵巢间肾样腺癌9例临床病理分析】。
Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn112141-20241217-00675
H Wang, J Liu, Y Cheng, S N Wang, F F Zhong, W Y Gu
<p><p><b>Objective:</b> To investigate the clinical and pathological characteristics, treatment and prognosis of endometriosis (EM)-associated ovarian mesonephric-like adenocarcinoma (MLA). <b>Methods:</b> Clinical and pathological data were collected from nine patients diagnosed with EM-associated ovarian MLA at the Obstetrics and Gynecology Hospital of Fudan University between January 2022 and December 2024. Histological slides were re-reviewed, immunohistochemical examination and molecular testing were performed, and patient follow-up was conducted. <b>Results:</b> (1) Clinical characteristics: the median age of the nine patients was 54 years (range: 38-69 years). All patients presented with a pelvic mass; five cases also reported abdominal pain. Tumor location included five cases in the right ovary, two in the left ovary, and two involving both ovaries. International Federation of Gynecology and Obstetrics (FIGO) staging showed 3 cases at stage Ⅰ, 4 at stage Ⅱ, and 2 at stage Ⅲ. (2) Pathological features: gross examination revealed mixed solid-cystic masses with solid areas appearing gray-white or yellow-brown; the median maximum tumor diameter was 9.0 cm (range: 2.6-13.0 cm). Microscopically, tumors exhibited various architectural patterns, including tubular, glandular, papillary, slit-like, sex cord-like, glomeruloid, and solid structures, with tubular and glandular patterns being most common. Tumor cells demonstrated mild to moderate nuclear atypia. Of the 11 tumor foci in the 9 cases, 8 showed coexistence of MLA with other tumor components, such as endometrioid carcinoma, borderline endometrioid or borderline seromucinous tumors. In 1 case of MLA mixed with a borderline endometrioid tumor, both components exhibited squamous metaplasia. Immunohistochemistry showed variable expression of GATA-binding protein 3, thyroid transcription factor-1, CD<sub>10</sub>, and calretinin, with positive rates of 9/11, 8/11, 5/11, and 3/6, respectively. Two tumor foci (2/11) exhibited focal expression of estrogen receptor and progesterone receptor. All cases displayed wild-type p53 expression. Molecular testing via next-generation sequencing in five patients revealed pathogenic mutations in the KRAS gene (5/5), with 3 cases (3/5) harboring additional pathogenic mutations in other genes. (3) Treatment and prognosis: all patients underwent surgery, supplemented by chemotherapy and (or) targeted therapy. Five patients underwent comprehensive staging surgery, four received cytoreductive surgery, and one patient received targeted therapy. The median follow-up duration was 7 months (range: 2-27 months). Three patients (3/9) experienced recurrence, and no deaths were reported during the follow-up period. <b>Conclusions:</b> EM-associated ovarian MLA demonstrates diverse morphological patterns and frequently coexists with other tumor types. Accurate diagnosis relies on an integrated evaluation of histomorphology, immunohistochemistry, and molecular testing. The pr
目的:探讨子宫内膜异位症(EM)相关卵巢间肾样腺癌(MLA)的临床病理特点、治疗及预后。方法:收集2022年1月至2024年12月在复旦大学妇产科医院诊断为em相关性卵巢MLA的9例患者的临床和病理资料。重新复查组织切片,进行免疫组化检查和分子检测,并进行患者随访。结果:(1)临床特征:9例患者年龄中位数54岁(范围38 ~ 69岁)。所有患者均表现为盆腔肿块;5例还报告腹痛。肿瘤位置包括5例在右卵巢,2例在左卵巢,2例累及双卵巢。国际妇产联合会(FIGO)分期:Ⅰ期3例,Ⅱ期4例,Ⅲ期2例。(2)病理特征:大体检查显示混合性实性囊性肿块,实区呈灰白色或黄褐色;中位最大肿瘤直径9.0 cm(范围2.6 ~ 13.0 cm)。显微镜下,肿瘤表现出多种结构模式,包括管状、腺状、乳头状、裂隙状、性索状、肾小球状和实性结构,其中管状和腺状结构最为常见。肿瘤细胞表现为轻度至中度核异型性。9例11个肿瘤灶中,8例MLA与其他肿瘤成分共存,如子宫内膜样癌、交界性子宫内膜样癌或交界性浆液性肿瘤。在1例MLA合并交界性子宫内膜样瘤中,两者均表现为鳞状化生。免疫组化显示gata结合蛋白3、甲状腺转录因子-1、CD10和calretinin的表达变化,阳性率分别为9/11、8/11、5/11和3/6。2个肿瘤灶(2/11)出现雌激素受体和孕激素受体的局灶性表达。所有病例均显示野生型p53表达。5例患者的新一代测序分子检测显示KRAS基因存在致病性突变(5/5),3例患者(3/5)在其他基因中存在额外的致病性突变。(3)治疗及预后:所有患者均行手术治疗,辅以化疗和(或)靶向治疗。5例患者接受了综合分期手术,4例患者接受了细胞减少手术,1例患者接受了靶向治疗。中位随访时间为7个月(范围:2-27个月)。3例(3/9)复发,随访期间无死亡报告。结论:em相关的卵巢MLA表现出多种形态模式,并经常与其他肿瘤类型共存。准确的诊断依赖于组织形态学、免疫组织化学和分子检测的综合评估。em相关卵巢MLA的主要治疗是手术,其次是辅助化疗。携带致病性KRAS p.G12C突变的患者可能受益于靶向治疗。卵巢MLA为侵袭性肿瘤,短期内易复发,预后较差。
{"title":"[Endometriosis-associated ovarian mesonephric-like adenocarcinoma:a clinicopathological analysis of 9 cases].","authors":"H Wang, J Liu, Y Cheng, S N Wang, F F Zhong, W Y Gu","doi":"10.3760/cma.j.cn112141-20241217-00675","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20241217-00675","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the clinical and pathological characteristics, treatment and prognosis of endometriosis (EM)-associated ovarian mesonephric-like adenocarcinoma (MLA). &lt;b&gt;Methods:&lt;/b&gt; Clinical and pathological data were collected from nine patients diagnosed with EM-associated ovarian MLA at the Obstetrics and Gynecology Hospital of Fudan University between January 2022 and December 2024. Histological slides were re-reviewed, immunohistochemical examination and molecular testing were performed, and patient follow-up was conducted. &lt;b&gt;Results:&lt;/b&gt; (1) Clinical characteristics: the median age of the nine patients was 54 years (range: 38-69 years). All patients presented with a pelvic mass; five cases also reported abdominal pain. Tumor location included five cases in the right ovary, two in the left ovary, and two involving both ovaries. International Federation of Gynecology and Obstetrics (FIGO) staging showed 3 cases at stage Ⅰ, 4 at stage Ⅱ, and 2 at stage Ⅲ. (2) Pathological features: gross examination revealed mixed solid-cystic masses with solid areas appearing gray-white or yellow-brown; the median maximum tumor diameter was 9.0 cm (range: 2.6-13.0 cm). Microscopically, tumors exhibited various architectural patterns, including tubular, glandular, papillary, slit-like, sex cord-like, glomeruloid, and solid structures, with tubular and glandular patterns being most common. Tumor cells demonstrated mild to moderate nuclear atypia. Of the 11 tumor foci in the 9 cases, 8 showed coexistence of MLA with other tumor components, such as endometrioid carcinoma, borderline endometrioid or borderline seromucinous tumors. In 1 case of MLA mixed with a borderline endometrioid tumor, both components exhibited squamous metaplasia. Immunohistochemistry showed variable expression of GATA-binding protein 3, thyroid transcription factor-1, CD&lt;sub&gt;10&lt;/sub&gt;, and calretinin, with positive rates of 9/11, 8/11, 5/11, and 3/6, respectively. Two tumor foci (2/11) exhibited focal expression of estrogen receptor and progesterone receptor. All cases displayed wild-type p53 expression. Molecular testing via next-generation sequencing in five patients revealed pathogenic mutations in the KRAS gene (5/5), with 3 cases (3/5) harboring additional pathogenic mutations in other genes. (3) Treatment and prognosis: all patients underwent surgery, supplemented by chemotherapy and (or) targeted therapy. Five patients underwent comprehensive staging surgery, four received cytoreductive surgery, and one patient received targeted therapy. The median follow-up duration was 7 months (range: 2-27 months). Three patients (3/9) experienced recurrence, and no deaths were reported during the follow-up period. &lt;b&gt;Conclusions:&lt;/b&gt; EM-associated ovarian MLA demonstrates diverse morphological patterns and frequently coexists with other tumor types. Accurate diagnosis relies on an integrated evaluation of histomorphology, immunohistochemistry, and molecular testing. The pr","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 6","pages":"469-476"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Impact of pre-pregnancy BMI on the cumulative live birth rate and perinatal outcomes in patients with PCOS undergoing first IVF/ICSI]. [孕前BMI对首次IVF/ICSI的PCOS患者累计活产率和围产儿结局的影响]。
Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn112141-20250312-00087
X Y Wang, J N Xu, M Li, C L Zhang, S D Zhang

Objective: To investigate the effect of pre-pregnancy body mass index (BMI) on the cumulative live birth rate (CLBR) and perinatal outcomes in women with polycystic ovary syndrome (PCOS) undergoing first in vitro fertilization or intracytoplasmic sperm injection (IVF/ICSI). Methods: The clinical data of 1 013 patients with PCOS who received first IVF/ICSI treatment in Reproductive Medicine Center, Henan Provincial People's Hospital from January 2017 to June 2020 were retrospectively analyzed. According to BMI China standard, they were divided into: normal weight group (18.5≤BMI<24.0 kg/m2, 388 cases), overweight group (24.0≤BMI<28.0 kg/m2, 367 cases), obese group (BMI≥28.0 kg/m2, 258 cases). The effect of BMI on CLBR was analyzed by univariate analysis, multivariate logistic regression analysis and smooth curve fitting. The role of homeostasis model assessment of insulin resistance index (HOMA-IR) in the process of BMI on CLBR was analyzed by mediation analysis. Results: Among three groups, female age, basal level of follicle stimulating hormone, type of infertility and ovulation induction regimens were similar (all P>0.05). The infertility duration, basal testosterone level, HOMA-IR, the ovulation induction time and the total gonadotropin dosage increased with BMI (all P<0.01), anti-Müllerian hormone, basal luteinizing hormone level, the number of retrieved oocytes and available embryos decreased with BMI (all P<0.05). CLBR decreased with BMI increasing [84.08% (301/358) vs 74.26% (251/338) vs 71.88% (161/224); P<0.001]. The incidence of hypertensive disorder in pregnancy was highest in obese group, while premature rupture of membranes rate, premature delivery rate, low birth weight rate and macrosomia birth rate were the lowest in normal weight group. After adjusting for confounding factors, both smooth curve fitting and multiple logistic regression analysis revealed a significant trend: CLBR declined with increasing BMI (OR=0.93, 95%CI: 0.89-0.97; P=0.002), with a reduction of 41% (OR=0.59, 95%CI: 0.39-0.91; P=0.020) in overweight group, and a reduction of 48% (OR=0.52, 95%CI: 0.32-0.83; P=0.010) in obese group. HOMA-IR mediated the effect of BMI on CLBR by 27.5% (P<0.05). Conclusions: High BMI before IVF/ICSI in PCOS patients negatively impacts CLBR and raises maternal and infant risks during pregnancy and the perinatal period. 27.5% of the effect of BMI on CLBR is mediated by HOMA-IR. Thus, PCOS patients should manage their BMI and enhance insulin sensitivity prior to pregnancy.

目的:探讨孕前体重指数(BMI)对首次体外受精或卵浆内单精子注射(IVF/ICSI)多囊卵巢综合征(PCOS)患者累积活产率(CLBR)及围产期结局的影响。方法:回顾性分析2017年1月至2020年6月河南省人民医院生殖医学中心首次IVF/ICSI治疗的1 013例PCOS患者的临床资料。按BMI中国标准分为:体重正常组(18.5≤BMI2, 388例)、超重组(24.0≤BMI2, 367例)、肥胖组(BMI≥28.0 kg/m2, 258例)。采用单因素分析、多因素logistic回归分析和平滑曲线拟合分析BMI对CLBR的影响。通过中介分析,分析胰岛素抵抗指数(HOMA-IR)稳态模型评估在CLBR BMI变化过程中的作用。结果:三组女性年龄、促卵泡激素基础水平、不孕症类型、促排卵方案差异无统计学意义(P < 0.05)。不孕持续时间、基础睾酮水平、HOMA-IR、促排卵时间、促性腺激素总剂量随BMI增加而增加(PPPOR=0.93, 95%CI: 0.89-0.97;P=0.002),减少了41% (OR=0.59, 95%CI: 0.39-0.91;P=0.020),减少48% (OR=0.52, 95%CI: 0.32-0.83;P=0.010)。HOMA-IR介导BMI对CLBR的影响为27.5% (p结论:PCOS患者体外受精/ICSI前高BMI会对CLBR产生负面影响,并增加妊娠期和围产期母婴风险。27.5%的BMI对CLBR的影响是由HOMA-IR介导的。因此,PCOS患者应在妊娠前控制BMI,提高胰岛素敏感性。
{"title":"[Impact of pre-pregnancy BMI on the cumulative live birth rate and perinatal outcomes in patients with PCOS undergoing first IVF/ICSI].","authors":"X Y Wang, J N Xu, M Li, C L Zhang, S D Zhang","doi":"10.3760/cma.j.cn112141-20250312-00087","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250312-00087","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the effect of pre-pregnancy body mass index (BMI) on the cumulative live birth rate (CLBR) and perinatal outcomes in women with polycystic ovary syndrome (PCOS) undergoing first in vitro fertilization or intracytoplasmic sperm injection (IVF/ICSI). <b>Methods:</b> The clinical data of 1 013 patients with PCOS who received first IVF/ICSI treatment in Reproductive Medicine Center, Henan Provincial People's Hospital from January 2017 to June 2020 were retrospectively analyzed. According to BMI China standard, they were divided into: normal weight group (18.5≤BMI<24.0 kg/m<sup>2</sup>, 388 cases), overweight group (24.0≤BMI<28.0 kg/m<sup>2</sup>, 367 cases), obese group (BMI≥28.0 kg/m<sup>2</sup>, 258 cases). The effect of BMI on CLBR was analyzed by univariate analysis, multivariate logistic regression analysis and smooth curve fitting. The role of homeostasis model assessment of insulin resistance index (HOMA-IR) in the process of BMI on CLBR was analyzed by mediation analysis. <b>Results:</b> Among three groups, female age, basal level of follicle stimulating hormone, type of infertility and ovulation induction regimens were similar (all <i>P</i>>0.05). The infertility duration, basal testosterone level, HOMA-IR, the ovulation induction time and the total gonadotropin dosage increased with BMI (all <i>P</i><0.01), anti-Müllerian hormone, basal luteinizing hormone level, the number of retrieved oocytes and available embryos decreased with BMI (all <i>P</i><0.05). CLBR decreased with BMI increasing [84.08% (301/358) vs 74.26% (251/338) vs 71.88% (161/224); <i>P</i><0.001]. The incidence of hypertensive disorder in pregnancy was highest in obese group, while premature rupture of membranes rate, premature delivery rate, low birth weight rate and macrosomia birth rate were the lowest in normal weight group. After adjusting for confounding factors, both smooth curve fitting and multiple logistic regression analysis revealed a significant trend: CLBR declined with increasing BMI (<i>OR</i>=0.93, 95%<i>CI</i>: 0.89-0.97; <i>P</i>=0.002), with a reduction of 41% (<i>OR</i>=0.59, 95%<i>CI</i>: 0.39-0.91; <i>P</i>=0.020) in overweight group, and a reduction of 48% (<i>OR</i>=0.52, 95%<i>CI</i>: 0.32-0.83; <i>P</i>=0.010) in obese group. HOMA-IR mediated the effect of BMI on CLBR by 27.5% (<i>P</i><0.05). <b>Conclusions:</b> High BMI before IVF/ICSI in PCOS patients negatively impacts CLBR and raises maternal and infant risks during pregnancy and the perinatal period. 27.5% of the effect of BMI on CLBR is mediated by HOMA-IR. Thus, PCOS patients should manage their BMI and enhance insulin sensitivity prior to pregnancy.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 6","pages":"439-449"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Expert consensus on gynecologic laparoendoscopic single port surgery (including vNOTES) 2025 edition]. 【妇科腹腔镜单口手术专家共识(含vNOTES) 2025版】。
Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn112141-20250127-00039
{"title":"[Expert consensus on gynecologic laparoendoscopic single port surgery (including vNOTES) 2025 edition].","authors":"","doi":"10.3760/cma.j.cn112141-20250127-00039","DOIUrl":"10.3760/cma.j.cn112141-20250127-00039","url":null,"abstract":"","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 6","pages":"417-421"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Association between postpartum blood loss volume and maternal adverse clinical outcomes]. [产后出血量与产妇不良临床结局的关系]。
Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn112141-20241024-00572
S Y Liang, J X Qu, H F Shi, Y Y Zhao

Objective: To investigate the relationship between postpartum hemorrhage (PPH) volume and the risk of adverse clinical outcomes in pregnant women. Methods: This was a retrospective cohort study of 41 494 deliveries at Peking University Third Hospital from 2012 to 2020. With PPH volume as the main exposure, the outcome indicators included: (1) Severe adverse outcomes: shock or embolism, abnormal coagulation function, abnormal liver function, and kidney injury; (2) General adverse outcomes: moderate to severe anemia, hypoalbuminemia, postpartum blood transfusion. Robust Poisson regression was employed to calculate the risk of each outcome index in pregnant women with different PPH volumes under the condition of controlling confounding factors, and to analyze the risk trends of each outcome index with the change of PPH volumes. Results: A total of 41 494 pregnant women were included in the study, including 9 959 cases (24.00%, 9 959/41 494), 23 974 cases (57.78%, 23 974/41 494), 5 235 cases (12.62%, 5 235/41 494), 1 144 cases (2.76%, 1 144/41 494), 508 cases (1.22%, 508/41 494), 208 cases (0.50%, 208/41 494), 207 cases (0.50%, 207/41 494) and 259 cases (0.62%, 259/41 494) pregnant women with PPH volume <250, 250-499, 500-749, 750-999, 1 000-1 249, 1 250-1 499, 1 500-1 999 and ≥2 000 ml, respectively. The risk of any serious adverse outcome, such as shock or embolism, abnormal coagulation function, abnormal liver function and kidney injury, showed a "J-shaped" relationship with PPH volume: risks remained stable (0.26%-0.59%) below 1 500 ml but increased significantly to 3.38% (RR=3.43, 95%CI: 1.14-10.35) at 1 500-1 999 ml and 5.02% (RR=4.53, 95%CI: 1.49-13.75) at ≥2 000 ml (all P<0.05). Moderate-to-severe anemia showed threshold effects at 750 ml (RR ranging from 7.21 to 8.53) and hypoalbuminemia at 1 250 ml (RR ranging from 3.24 to 3.83), with risks plateauing beyond these thresholds (all P<0.05). Conclusion: It is suggested that 750 ml, 1 250 ml and 1 500 ml should be used as the key intervention thresholds, corresponding to the initiation thresholds of anemia, hypoalbuminemia management and multidisciplinary intensive care, respectively, so as to provide a new reference for optimizing the clinical diagnosis and treatment strategy of PPH.

目的:探讨孕妇产后出血(PPH)量与不良临床结局风险的关系。方法:对2012 - 2020年北京大学第三医院分娩的41494例产妇进行回顾性队列研究。以PPH量为主要暴露,结局指标包括:(1)严重不良结局:休克或栓塞、凝血功能异常、肝功能异常、肾损伤;(2)一般不良结局:中重度贫血、低白蛋白血症、产后输血。采用稳健泊松回归,在控制混杂因素的条件下,计算不同PPH量孕妇各结局指标的风险,分析各结局指标随PPH量变化的风险趋势。结果:共纳入41 494例孕妇,其中:1 500 ~ 1 999 ml PPH量RR=3.43, 95%CI: 1.14 ~ 10.35, 5.02% (RR=4.53, 95%CI: 5.02%): 9 959例(24.00%,9 959/41 494),23 974例(57.78%,23 974/41 494),5 235例(12.62%,5 235/41 494),1 144例(2.76%,1 144/41 494),508例(1.22%,508/41 494),208例(0.50%,208/41 494),207例(0.50%,207/41 494),259例(0.62%,259/41 494)孕妇PPH量RR=3.43, 95%CI: 1.14 ~ 10.35;1.49-13.75)≥2 000 ml时(所有PRR范围为7.21 - 8.53),低白蛋白血症为1 250 ml时(RR范围为3.24 - 3.83),超过这些阈值后风险趋于稳定(所有p)。建议将750 ml、1 250 ml和1 500 ml作为关键干预阈值,分别对应贫血、低白蛋白血症管理和多学科重症监护的起始阈值,为优化PPH临床诊疗策略提供新的参考。
{"title":"[Association between postpartum blood loss volume and maternal adverse clinical outcomes].","authors":"S Y Liang, J X Qu, H F Shi, Y Y Zhao","doi":"10.3760/cma.j.cn112141-20241024-00572","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20241024-00572","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the relationship between postpartum hemorrhage (PPH) volume and the risk of adverse clinical outcomes in pregnant women. <b>Methods:</b> This was a retrospective cohort study of 41 494 deliveries at Peking University Third Hospital from 2012 to 2020. With PPH volume as the main exposure, the outcome indicators included: (1) Severe adverse outcomes: shock or embolism, abnormal coagulation function, abnormal liver function, and kidney injury; (2) General adverse outcomes: moderate to severe anemia, hypoalbuminemia, postpartum blood transfusion. Robust Poisson regression was employed to calculate the risk of each outcome index in pregnant women with different PPH volumes under the condition of controlling confounding factors, and to analyze the risk trends of each outcome index with the change of PPH volumes. <b>Results:</b> A total of 41 494 pregnant women were included in the study, including 9 959 cases (24.00%, 9 959/41 494), 23 974 cases (57.78%, 23 974/41 494), 5 235 cases (12.62%, 5 235/41 494), 1 144 cases (2.76%, 1 144/41 494), 508 cases (1.22%, 508/41 494), 208 cases (0.50%, 208/41 494), 207 cases (0.50%, 207/41 494) and 259 cases (0.62%, 259/41 494) pregnant women with PPH volume <250, 250-499, 500-749, 750-999, 1 000-1 249, 1 250-1 499, 1 500-1 999 and ≥2 000 ml, respectively. The risk of any serious adverse outcome, such as shock or embolism, abnormal coagulation function, abnormal liver function and kidney injury, showed a \"J-shaped\" relationship with PPH volume: risks remained stable (0.26%-0.59%) below 1 500 ml but increased significantly to 3.38% (<i>RR</i>=3.43, 95%<i>CI</i>: 1.14-10.35) at 1 500-1 999 ml and 5.02% (<i>RR</i>=4.53, 95%<i>CI</i>: 1.49-13.75) at ≥2 000 ml (all <i>P</i><0.05). Moderate-to-severe anemia showed threshold effects at 750 ml (<i>RR</i> ranging from 7.21 to 8.53) and hypoalbuminemia at 1 250 ml (<i>RR</i> ranging from 3.24 to 3.83), with risks plateauing beyond these thresholds (all <i>P</i><0.05). <b>Conclusion:</b> It is suggested that 750 ml, 1 250 ml and 1 500 ml should be used as the key intervention thresholds, corresponding to the initiation thresholds of anemia, hypoalbuminemia management and multidisciplinary intensive care, respectively, so as to provide a new reference for optimizing the clinical diagnosis and treatment strategy of PPH.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 6","pages":"422-429"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Application of CA125 elimination rate constant K score in prognostic forecast of patients undergoing interval debulking surgery for high grade serous ovarian cancer]. [CA125清除率常数K评分在高级别浆液性卵巢癌间歇减容手术患者预后预测中的应用]。
Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn112141-20250102-00001
H D Liu, H L Wu, L L Ma, Y Cui, S W Wang, G H Shen

Objective: To investigate the predictive value of the cancer antigen 125 (CA125) elimination rate constant K (KELIM) score for no visible residual disease (R0) and prognosis in high-grade serous ovarian carcinoma (HGSOC) patients undergoing neoadjuvant chemotherapy (NACT)+interval debulking surgery (IDS). Methods: A retrospective analysis was conducted on 78 HGSOC patients treated with NACT+IDS at Beijing Hospital, from June 2014 to June 2024. The KELIM score was calculated, and its predictive value for R0 resection, chemotherapy response score (CRS), platinum-free interval (PFI), progression-free survival (PFS) time, and overall survival (OS) time was analyzed. Results: (1) The mean age at diagnosis was (61.9±9.9) years. The mean KELIM score was 1.1±0.4, with 44 patients having KELIM score≥1 and 34 having KELIM score <1. (2) Patients with KELIM score ≥1 had significantly higher rates of R0 resection (84% vs 56%; P=0.006), CRS3 grading (41% vs 0; P<0.001), and PFI ≥6 months (84% vs 53%; P=0.04) compared to those with KELIM score <1. Additionally, the median PFS time (18.7 vs 13.2 months; P<0.001) and OS time (34.8 vs 29.9 months; P=0.007) were significantly longer in the KELIM score ≥1 group. Chemosensitivity: patients with PFI <6 months had a significantly lower median KELIM score than those with PFI ≥6 months (0.8 vs 1.2; P=0.005). Surgical outcome: patients achieving R0 resection had a significantly higher median KELIM score than those without R0 (1.2 vs 0.7; P<0.001). (3) Univariate analysis identified non-R0 resection, CRS3 grading, lack of poly adenosine diphosphate ribose polymerase (PARP) inhibitor maintenance therapy, and KELIM score <1 as significant risk factors for OS time (all P<0.05). Multivariate analysis confirmed non-R0 resection (HR=3.78,95%CI: 1.13-12.66; P=0.031), no PARP inhibitor maintenance (HR=7.41,95%CI:1.82-30.15; P=0.005), and KELIM score <1 (HR=5.14,95%CI:1.41-18.72; P=0.013) as independent risk factors for OS time. Conclusions: The KELIM score may serve as a predictive marker for chemosensitivity, R0 resection, PFS time, and OS time in HGSOC patients undergoing NACT+IDS. KELIM score<1 is an independent risk factor for OS.

目的:探讨癌抗原125 (CA125)消除速率常数K (KELIM)评分对高级别浆液性卵巢癌(HGSOC)患者新辅助化疗(NACT)+间期减容手术(IDS)无可见残留病(R0)及预后的预测价值。方法:回顾性分析2014年6月至2024年6月北京医院接受NACT+IDS治疗的78例HGSOC患者。计算KELIM评分,并分析其对R0切除、化疗反应评分(CRS)、无铂期(PFI)、无进展生存期(PFS)时间、总生存期(OS)时间的预测价值。结果:(1)平均诊断年龄为(61.9±9.9)岁。平均KELIM评分为1.1±0.4,其中KELIM评分≥1者44例,KELIM评分P=0.006者34例),CRS3分级(41% vs 0;(PP=0.04)与KELIM评分≥1组(PP=0.007)相比,病程明显延长。化疗敏感性:PFI患者P=0.005)。手术结果:完成R0切除的患者的中位KELIM评分显著高于未完成R0切除的患者(1.2 vs 0.7;PPHR = 3.78, 95% ci: 1.13—-12.66;P=0.031),无PARP抑制剂维持(HR=7.41,95%CI:1.82 ~ 30.15;P=0.005), KELIM评分HR=5.14,95%CI:1.41 ~ 18.72;P=0.013)为OS时间的独立危险因素。结论:KELIM评分可作为HGSOC患者接受NACT+IDS化疗敏感性、R0切除、PFS时间和OS时间的预测指标。编织毯得分
{"title":"[Application of CA<sub>125</sub> elimination rate constant K score in prognostic forecast of patients undergoing interval debulking surgery for high grade serous ovarian cancer].","authors":"H D Liu, H L Wu, L L Ma, Y Cui, S W Wang, G H Shen","doi":"10.3760/cma.j.cn112141-20250102-00001","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250102-00001","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the predictive value of the cancer antigen 125 (CA<sub>125</sub>) elimination rate constant K (KELIM) score for no visible residual disease (R0) and prognosis in high-grade serous ovarian carcinoma (HGSOC) patients undergoing neoadjuvant chemotherapy (NACT)+interval debulking surgery (IDS). <b>Methods:</b> A retrospective analysis was conducted on 78 HGSOC patients treated with NACT+IDS at Beijing Hospital, from June 2014 to June 2024. The KELIM score was calculated, and its predictive value for R0 resection, chemotherapy response score (CRS), platinum-free interval (PFI), progression-free survival (PFS) time, and overall survival (OS) time was analyzed. <b>Results:</b> (1) The mean age at diagnosis was (61.9±9.9) years. The mean KELIM score was 1.1±0.4, with 44 patients having KELIM score≥1 and 34 having KELIM score <1. (2) Patients with KELIM score ≥1 had significantly higher rates of R0 resection (84% vs 56%; <i>P</i>=0.006), CRS3 grading (41% vs 0; <i>P</i><0.001), and PFI ≥6 months (84% vs 53%; <i>P</i>=0.04) compared to those with KELIM score <1. Additionally, the median PFS time (18.7 vs 13.2 months; <i>P</i><0.001) and OS time (34.8 vs 29.9 months; <i>P</i>=0.007) were significantly longer in the KELIM score ≥1 group. Chemosensitivity: patients with PFI <6 months had a significantly lower median KELIM score than those with PFI ≥6 months (0.8 vs 1.2; <i>P</i>=0.005). Surgical outcome: patients achieving R0 resection had a significantly higher median KELIM score than those without R0 (1.2 vs 0.7; <i>P</i><0.001). (3) Univariate analysis identified non-R0 resection, CRS3 grading, lack of poly adenosine diphosphate ribose polymerase (PARP) inhibitor maintenance therapy, and KELIM score <1 as significant risk factors for OS time (all <i>P</i><0.05). Multivariate analysis confirmed non-R0 resection (<i>HR</i>=3.78,95%<i>CI</i>: 1.13-12.66; <i>P</i>=0.031), no PARP inhibitor maintenance (<i>HR</i>=7.41,95%<i>CI</i>:1.82-30.15; <i>P</i>=0.005), and KELIM score <1 (<i>HR</i>=5.14,95%<i>CI</i>:1.41-18.72; <i>P</i>=0.013) as independent risk factors for OS time. <b>Conclusions:</b> The KELIM score may serve as a predictive marker for chemosensitivity, R0 resection, PFS time, and OS time in HGSOC patients undergoing NACT+IDS. KELIM score<1 is an independent risk factor for OS.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 6","pages":"461-468"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinicopathological features and prognosis of 117 cases of fumarate hydratase-deficient uterine leiomyomas]. 117例富马酸水合酶缺乏型子宫平滑肌瘤的临床病理特征及预后分析
Pub Date : 2025-06-25 DOI: 10.3760/cma.j.cn112141-20250205-00040
W N Yu, S Y Pan, C Wang, Z D Huang, X L Wang, S Zhu, Y Ding, X L Wang
<p><p><b>Objective:</b> To explore the clinicopathological characteristics and prognosis of fumarate hydratase-deficient uterine leiomyoma (FH-dUL). <b>Methods:</b> Clinical data and follow-up information for 117 patients with FH-dUL diagnosed through surgical pathology and immunohistochemistry in the First Affiliated Hospital of Nanjing Medical University from January 2020 to December 2024, were collected. A control group of 130 patients with common uterine leiomyomas was also included. The differences between the two groups in clinical, imaging, and pathological characteristics were compared. Additionally, recurrence rates, fertility outcomes for FH-dUL patients, and the incidence of renal cancer in FH germline mutation carriers were monitored. <b>Results:</b> (1) Comparison of clinicopathological characteristics: the median age of 117 FH-dUL patients was 35 years, and the median age at first diagnosis of uterine leiomyomas was 29 years, both significantly younger than the control group (41 and 36 years; both <i>P</i><0.01). The FH-dUL group showed significantly higher incidences of uterine myomectomy, multiple leiomyomas, diffusion restriction on pelvic magnetic resonance imaging diffusion weighted imaging, and typical pathological features (candelabra-like vessels, bizarre nuclei, cytoplasmic eosinophilic globules, perinuclear halo, cellular atypia) and higher ultrasound blood flow score (all <i>P</i><0.05). Of the 30 FH-dUL patients who underwent genetic testing, 9 had germline mutations, 3 had somatic mutations, and 6 had mutations of unclear origin. Among the 9 FH gene germline mutation patients, 2 had already developed renal cell carcinoma. (2) Recurrence analysis: among the 56 patients who underwent uterine myomectomy, 22 (39.3%, 22/56) experienced recurrence during follow-up, compared to 12 (21.8%, 12/55) of the 55 patients in the control group, the difference between the two groups was statistically significant (<i>P</i>=0.046). Multivariate binary logistic regression analysis showed that cellular leiomyomas (<i>OR</i>=9.489, 95%<i>CI</i>: 1.740-51.755; <i>P</i>=0.009) and multiple uterine leiomyomas (<i>OR</i>=10.709, 95%<i>CI</i>: 1.354-84.683; <i>P</i>=0.025) were significant risk factors for recurrence in FH-dUL. (3) Fertility analysis: among the 66 FH-dUL patients who underwent fertility-preserving surgery, 16 had the intention to have fertility desire, only 2 (2/16) completed their fertility plans during follow-up. <b>Conclusions:</b> Clinicopathological features and imaging features help to differentiate FH-dUL from common type uterine fibroids, but lack specificity, and the diagnosis of FH-dUL is based on immunohistochemistry. The recurrence rate after resection of FH-dUL is high, and cellular and multiple leiomyomas are important predictors of recurrence. It is crucial to perform genetic testing, genetic counseling, drug treatment to prevent recurrence, fertility guidance, and long-term comprehensive management after surgery f
目的:探讨富马酸水合酶缺乏型子宫平滑肌瘤(FH-dUL)的临床病理特点及预后。方法:收集2020年1月至2024年12月南京医科大学第一附属医院经手术病理及免疫组化诊断为FH-dUL的117例患者的临床资料及随访资料。130例普通子宫平滑肌瘤患者作为对照组。比较两组在临床、影像学、病理等方面的差异。此外,还监测了FH- dul患者的复发率、生育结果以及FH种系突变携带者的肾癌发病率。结果:(1)临床病理特征比较:117例FH-dUL患者的中位年龄为35岁,首次诊断子宫平滑肌瘤的中位年龄为29岁,均明显低于对照组(41岁和36岁;购买力平价= 0.046)。多元二元logistic回归分析显示细胞性平滑肌瘤(OR=9.489, 95%CI: 1.740 ~ 51.755;P=0.009)和多发性子宫平滑肌瘤(OR=10.709, 95%CI: 1.354 ~ 84.683;P=0.025)是FH-dUL复发的重要危险因素。(3)生育分析:66例行保留生育手术的FH-dUL患者中,有生育意愿的有16例,随访期间仅有2例(2/16)完成了生育计划。结论:FH-dUL的临床病理特征和影像学特征有助于与普通型子宫肌瘤的鉴别,但缺乏特异性,FH-dUL的诊断主要基于免疫组织化学。FH-dUL切除术后复发率高,细胞性和多发性平滑肌瘤是复发的重要预测因素。对FH-dUL进行基因检测、遗传咨询、预防复发的药物治疗、生育指导和术后长期综合管理是治疗FH-dUL的关键。
{"title":"[Clinicopathological features and prognosis of 117 cases of fumarate hydratase-deficient uterine leiomyomas].","authors":"W N Yu, S Y Pan, C Wang, Z D Huang, X L Wang, S Zhu, Y Ding, X L Wang","doi":"10.3760/cma.j.cn112141-20250205-00040","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20250205-00040","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To explore the clinicopathological characteristics and prognosis of fumarate hydratase-deficient uterine leiomyoma (FH-dUL). &lt;b&gt;Methods:&lt;/b&gt; Clinical data and follow-up information for 117 patients with FH-dUL diagnosed through surgical pathology and immunohistochemistry in the First Affiliated Hospital of Nanjing Medical University from January 2020 to December 2024, were collected. A control group of 130 patients with common uterine leiomyomas was also included. The differences between the two groups in clinical, imaging, and pathological characteristics were compared. Additionally, recurrence rates, fertility outcomes for FH-dUL patients, and the incidence of renal cancer in FH germline mutation carriers were monitored. &lt;b&gt;Results:&lt;/b&gt; (1) Comparison of clinicopathological characteristics: the median age of 117 FH-dUL patients was 35 years, and the median age at first diagnosis of uterine leiomyomas was 29 years, both significantly younger than the control group (41 and 36 years; both &lt;i&gt;P&lt;/i&gt;&lt;0.01). The FH-dUL group showed significantly higher incidences of uterine myomectomy, multiple leiomyomas, diffusion restriction on pelvic magnetic resonance imaging diffusion weighted imaging, and typical pathological features (candelabra-like vessels, bizarre nuclei, cytoplasmic eosinophilic globules, perinuclear halo, cellular atypia) and higher ultrasound blood flow score (all &lt;i&gt;P&lt;/i&gt;&lt;0.05). Of the 30 FH-dUL patients who underwent genetic testing, 9 had germline mutations, 3 had somatic mutations, and 6 had mutations of unclear origin. Among the 9 FH gene germline mutation patients, 2 had already developed renal cell carcinoma. (2) Recurrence analysis: among the 56 patients who underwent uterine myomectomy, 22 (39.3%, 22/56) experienced recurrence during follow-up, compared to 12 (21.8%, 12/55) of the 55 patients in the control group, the difference between the two groups was statistically significant (&lt;i&gt;P&lt;/i&gt;=0.046). Multivariate binary logistic regression analysis showed that cellular leiomyomas (&lt;i&gt;OR&lt;/i&gt;=9.489, 95%&lt;i&gt;CI&lt;/i&gt;: 1.740-51.755; &lt;i&gt;P&lt;/i&gt;=0.009) and multiple uterine leiomyomas (&lt;i&gt;OR&lt;/i&gt;=10.709, 95%&lt;i&gt;CI&lt;/i&gt;: 1.354-84.683; &lt;i&gt;P&lt;/i&gt;=0.025) were significant risk factors for recurrence in FH-dUL. (3) Fertility analysis: among the 66 FH-dUL patients who underwent fertility-preserving surgery, 16 had the intention to have fertility desire, only 2 (2/16) completed their fertility plans during follow-up. &lt;b&gt;Conclusions:&lt;/b&gt; Clinicopathological features and imaging features help to differentiate FH-dUL from common type uterine fibroids, but lack specificity, and the diagnosis of FH-dUL is based on immunohistochemistry. The recurrence rate after resection of FH-dUL is high, and cellular and multiple leiomyomas are important predictors of recurrence. It is crucial to perform genetic testing, genetic counseling, drug treatment to prevent recurrence, fertility guidance, and long-term comprehensive management after surgery f","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 6","pages":"450-460"},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical application value of combined focused ultrasound ablation surgery and hysteroscopy in the treatment of solitary type Ⅱ submucosal uterine fibroids with maximum diameter more than 5 cm]. 【聚焦超声消融联合宫腔镜治疗最大直径大于5 cm的孤立型Ⅱ粘膜下子宫肌瘤的临床应用价值】。
Pub Date : 2025-05-25 DOI: 10.3760/cma.j.cn112141-20241022-00566
H Y Cheng, C M Sang, Y J Kang, L Zhao, K Ding, S P Zhao

Objective: To explore the effectiveness and application value of focused ultrasound ablation surgery (FUAS) combined with hysteroscopic surgery in treating solitary type Ⅱ submucosal uterine fibroids with maximum diameter >5 cm. Methods: Clinical data of 35 patients with a single type Ⅱ submucosal uterine fibroid with maximum diameter greater than 5 cm who underwent FUAS combined with hysteroscopic surgery at Qingdao Women and Children's Hospital from June 2020 to December 2023 were collected. The clinical characteristics, treatments and treatment outcomes were retrospectively analyzed. Results: (1) Clinical characteristics: the mean age of the 35 patients was (36.7±6.6) years, with a median maximum diameter of fibroids of 56 mm (range: 51-80 mm). All patients presented with symptoms of menorrhagia, median menstrual bleeding score was 5 points (ranged from 3 to 5 points), and 34 cases (97.1%, 34/35) had concomitant anemia, the mean hemoglobin was (83.1±13.8) g/L of 35 patients. (2) Treatments: all 35 patients underwent FUAS treatment initially, with a lesion ablation rate ranging from 69.7% to 97.9% (median:90.7%), and no complications occurred. After FUAS treatment, the volume of fibroids decreased in all patients, with a volume reduction rate ranging from 30.57% to 87.22% (median:76.03%). Hysteroscopic surgery was performed 3-14 months (median: 5 months) after FUAS to remove the necrotic fibroid tissue, achieving a 100.0% (35/35) fibroid resection rate. Only 1 patient developed complications of hyperhyderation syndrome during hysteroscopic surgery, and no complications occurred in the remaining patients. (3) Evaluation of efficacy: after FUAS pretreatment, the maximum diameter of fibroids in the 35 patients decreased significantly (Z=-5.171, P<0.001), as did the volume of fibroids (Z=-5.159, P<0.001). The hemoglobin level increased significantly compared to the level before FUAS in all cases (t=-8.657, P<0.001), and median menstrual bleeding score decreased to 2 points (range: 1-3 points), significantly lower than original level (Z=-5.292, P<0.001). At the 3-month follow-up after hysteroscopic surgery, all patients were free of anemia symptoms, with menstrual bleeding scores totally decreased to 1 point, significantly lower than that before hysteroscopic surgery (Z=-4.786, P<0.001); hemoglobin level [(118.7±5.6) g/L] significantly increased compared to that before hysteroscopic surgery (t=-9.258, P<0.001). All patients underwent gynecological transvaginal ultrasound re-examination, which did not reveal any residual fibroids. Conclusion: FUAS combined with hysteroscopic surgery is effective in treating solitary type Ⅱ submucosal uterine fibroids with maximum diameter >5 cm, providing a new treatment option for patients.

目的:探讨聚焦超声消融术(FUAS)联合宫腔镜手术治疗最大直径bbb50 cm孤立型Ⅱ粘膜下子宫肌瘤的疗效及应用价值。方法:收集2020年6月至2023年12月青岛市妇女儿童医院行FUAS联合宫腔镜手术的35例最大直径大于5 cm的单一类型Ⅱ粘膜下子宫肌瘤患者的临床资料。回顾性分析两组患者的临床特点、治疗方法及治疗效果。结果:(1)临床特征:35例患者平均年龄(36.7±6.6)岁,肌瘤最大中位直径56 mm(范围51 ~ 80 mm)。所有患者均出现月经过多症状,月经出血评分中位数为5分(范围3 ~ 5分),34例(97.1%,34/35)合并贫血,35例患者平均血红蛋白为(83.1±13.8)g/L。(2)治疗:35例患者初始均接受FUAS治疗,病灶消融率为69.7% ~ 97.9%(中位数:90.7%),无并发症发生。经FUAS治疗后,所有患者肌瘤体积均减小,体积减小率为30.57% ~ 87.22%(中位数:76.03%)。术后3-14个月(中位数:5个月)行宫腔镜手术切除坏死肌瘤组织,肌瘤切除率达100.0%(35/35)。宫腔镜手术中仅有1例患者出现过水合综合征并发症,其余患者均无并发症发生。(3)疗效评价:35例患者经FUAS处理后肌瘤最大直径明显减小(Z=-5.171, PZ=-5.159, Pt=-8.657, PZ=-5.292, PZ=-4.786, Pt=-9.258, p)结论:FUAS联合宫腔镜手术治疗最大直径> ~ 5 cm的孤立型Ⅱ粘膜下肌瘤有效,为患者提供了一种新的治疗选择。
{"title":"[Clinical application value of combined focused ultrasound ablation surgery and hysteroscopy in the treatment of solitary type Ⅱ submucosal uterine fibroids with maximum diameter more than 5 cm].","authors":"H Y Cheng, C M Sang, Y J Kang, L Zhao, K Ding, S P Zhao","doi":"10.3760/cma.j.cn112141-20241022-00566","DOIUrl":"https://doi.org/10.3760/cma.j.cn112141-20241022-00566","url":null,"abstract":"<p><p><b>Objective:</b> To explore the effectiveness and application value of focused ultrasound ablation surgery (FUAS) combined with hysteroscopic surgery in treating solitary type Ⅱ submucosal uterine fibroids with maximum diameter >5 cm. <b>Methods:</b> Clinical data of 35 patients with a single type Ⅱ submucosal uterine fibroid with maximum diameter greater than 5 cm who underwent FUAS combined with hysteroscopic surgery at Qingdao Women and Children's Hospital from June 2020 to December 2023 were collected. The clinical characteristics, treatments and treatment outcomes were retrospectively analyzed. <b>Results:</b> (1) Clinical characteristics: the mean age of the 35 patients was (36.7±6.6) years, with a median maximum diameter of fibroids of 56 mm (range: 51-80 mm). All patients presented with symptoms of menorrhagia, median menstrual bleeding score was 5 points (ranged from 3 to 5 points), and 34 cases (97.1%, 34/35) had concomitant anemia, the mean hemoglobin was (83.1±13.8) g/L of 35 patients. (2) Treatments: all 35 patients underwent FUAS treatment initially, with a lesion ablation rate ranging from 69.7% to 97.9% (median:90.7%), and no complications occurred. After FUAS treatment, the volume of fibroids decreased in all patients, with a volume reduction rate ranging from 30.57% to 87.22% (median:76.03%). Hysteroscopic surgery was performed 3-14 months (median: 5 months) after FUAS to remove the necrotic fibroid tissue, achieving a 100.0% (35/35) fibroid resection rate. Only 1 patient developed complications of hyperhyderation syndrome during hysteroscopic surgery, and no complications occurred in the remaining patients. (3) Evaluation of efficacy: after FUAS pretreatment, the maximum diameter of fibroids in the 35 patients decreased significantly (<i>Z</i>=-5.171, <i>P</i><0.001), as did the volume of fibroids (<i>Z</i>=-5.159, <i>P</i><0.001). The hemoglobin level increased significantly compared to the level before FUAS in all cases (<i>t</i>=-8.657, <i>P</i><0.001), and median menstrual bleeding score decreased to 2 points (range: 1-3 points), significantly lower than original level (<i>Z</i>=-5.292, <i>P</i><0.001). At the 3-month follow-up after hysteroscopic surgery, all patients were free of anemia symptoms, with menstrual bleeding scores totally decreased to 1 point, significantly lower than that before hysteroscopic surgery (<i>Z</i>=-4.786, <i>P</i><0.001); hemoglobin level [(118.7±5.6) g/L] significantly increased compared to that before hysteroscopic surgery (<i>t</i>=-9.258, <i>P</i><0.001). All patients underwent gynecological transvaginal ultrasound re-examination, which did not reveal any residual fibroids. <b>Conclusion:</b> FUAS combined with hysteroscopic surgery is effective in treating solitary type Ⅱ submucosal uterine fibroids with maximum diameter >5 cm, providing a new treatment option for patients.</p>","PeriodicalId":10050,"journal":{"name":"中华妇产科杂志","volume":"60 5","pages":"363-371"},"PeriodicalIF":0.0,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华妇产科杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1